KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

BackgroundKRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied...

Full description

Bibliographic Details
Main Authors: Emerik Osterlund, Ari Ristimäki, Soili Kytölä, Teijo Kuopio, Eetu Heervä, Timo Muhonen, Päivi Halonen, Raija Kallio, Leena-Maija Soveri, Jari Sundström, Mauri Keinänen, Annika Ålgars, Raija Ristamäki, Halfdan Sorbye, Per Pfeiffer, Luís Nunes, Tapio Salminen, Annamarja Lamminmäki, Markus J. Mäkinen, Tobias Sjöblom, Helena Isoniemi, Bengt Glimelius, Pia Osterlund
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-02-01
Series:Frontiers in Oncology
Subjects:
colorectal cancer
metastatic
KRAS mutation
KRAS-G12C mutation
population-based
real-world
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.826073/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.826073/full

Similar Items